Properties
- Form
- khsnari
- Dosage mg
- 50მგ/
- Pack
- 10
What is it?
DROXINAT Trade name: DROXINAT International Nonproprietary Name: Ethylmethylhydroxypyridine succinate Chemical name: 2-ethyl-6-methyl-3-hydroxypyridine succinate Dosage form: Solution for injection 50 mg/ml Description: Colorless or slightly brown solution Composition: Active substance: Ethylmethylhydroxypyridine succinate 50 mg. Excipients: Sodium metabisulfite (E 223), Water for injections. Pharmacotherapeutic group: Antioxidant agent. See blog: More than an antioxidant: Everything you need to know about Droxinat Pharmacological properties: Pharmacodynamics It has antioxidant, antihypoxic, membrane-stabilizing, nootropic, stress-protective, anticonvulsant, anxiolytic effects. The preparation increases the body's resistance to various damaging factors (shock, hypoxia, ischemia, trauma, cerebrovascular accident, intoxication with alcohol and antipsychotics (neuroleptics)). Droxinat improves cerebral metabolism and cerebral circulation, improves blood microcirculation and rheological properties, reduces platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces total cholesterol and low-density lipoprotein content. It reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis. The mechanism of action of Droxinat is due to its antihypoxant, antioxidant, and membrane-protective effects. It inhibits lipid peroxidation processes, activates superoxide dismutase, increases the ratio of lipids to proteins, reduces lipid layer viscosity, and increases membrane permeability. It has a modulating effect on the activity of membrane-bound enzymes (phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptors (benzodiazepine, acetylcholine, GABA), enhances their ability to bind to ligands, and helps promote the structural-functional organization of biomembranes, increases neurotransmitter activity, and improves synaptic processes. Droxinat increases dopamine concentration in the brain. The mechanism of action is due to Droxinat's ability to enhance the compensatory activation of aerobic glycolysis, reduce the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions by increasing ATP content and creatine phosphate through stabilization of cellular membranes. Pharmacokinetics After intramuscular administration, it is detected in blood plasma 4 hours after administration. The time to reach maximum concentration (Tmax) is 0.45-0.5 hours. Cmax at a dose of 400-500 mg is 3.5-4.0 mcg/ml. Droxinat is rapidly distributed to organs and tissues and rapidly eliminated from the body. The mean retention time (MRT) after intramuscular administration is 0.7-1.3 hours. The preparation is mainly excreted in urine, in the form of glucuronide and in a small amount unchanged. Indications for use: Acute cerebrovascular disorders; Dyscirculatory encephalopathy; Vegetative dystonia syndrome; Mild cognitive disorders of atherosclerotic genesis; Anxiety disorders in neurotic and neurosis-like conditions; Relief of abstinence syndrome in alcoholism, with a predominance of neurosis-like and vegetative-vascular disorders; Acute intoxication with antipsychotics; Acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis). Method of administration and dosage Dosage regimen: Intramuscularly or intravenously (bolus or drip). When administered by infusion, the preparation should be diluted in isotonic sodium chloride solution. Droxinat is administered bolus slowly over 5-7 minutes, drip at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg. In acute cerebrovascular disorders, Droxinat is used for the first 10-14 days intravenously drip at 200-500 mg 2-4 times a day, then intramuscularly at 200-250 mg 2-3 times a day for 2 weeks. In dyscirculatory encephalopathy in the decompensation phase, Droxinat should be administered intravenously bolus or drip at a dose of 200-500 mg 1-2 times a day for 14 days. Then intramuscularly at 100-250 mg/day for the next 2 weeks. For course prophylaxis of dyscirculatory encephalopathy, the preparation is administered intramuscularly at a dose of 200-250 mg twice a day for 10-14 days. In mild cognitive disorders in elderly patients and in anxiety disorders, the preparation is used intramuscularly at 100-300 mg/day for 14-30 days. In abstinence alcoholic syndrome, Droxinat is administered at a dose of 200-500 mg intravenously drip or intramuscularly 2-3 times a day for 5-7 days. In acute intoxication with antipsychotics, the preparation is administered intravenously at a dose of 200-500 mg/day for 7-14 days. In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the preparation is prescribed on the first day, both preoperatively and postoperatively. The doses to be administered depend on the form and severity of the disease, the extent of the process, and the variants of the clinical course. The preparation should be withdrawn gradually, only after a stable positive clinical and laboratory effect. In acute edematous (interstitial) pancreatitis – the preparation is prescribed at 200-500 mg 3 times a day, intravenously drip (in isotonic sodium chloride solution) and intramuscularly. Mild degree of necrotizing pancreatitis – 100-200 mg 3 times a day intravenously drip (in isotonic sodium chloride solution) and intramuscularly. Moderate severity – 200 mg 3 times a day, intravenously drip (in isotonic sodium chloride solution). Severe course – pulse dose of 800 mg on the first day, with a twice-daily administration regimen, then 200-500 mg twice a day with gradual reduction of the daily dose. Extremely severe course – initial dose of 800 mg/day until stable relief of pancreatogenic shock manifestations, depending on the stability of the condition – 300-500 mg twice a day intravenously drip (in isotonic sodium chloride solution), with gradual reduction of the daily dose. Side effects Possible nausea, xerostomia, drowsiness, allergic reactions. Contraindications Hypersensitivity to the active substance or any of the excipients. Acute disorders of liver and kidney function. Pregnancy and lactation period. Children and adolescents. Overdose In case of overdose, drowsiness may occur. Special instructions The degree of limitation is determined based on individual intolerance to the preparation. Excipients Droxinat contains sodium metabisulfite (E 223), which rarely causes serious hypersensitivity reactions and bronchospasm. Pregnancy and lactation No clinical studies have been conducted on the safety of the preparation during pregnancy and lactation. Therefore, Droxinat is not recommended during pregnancy and in women of childbearing age who do not use effective contraception, and during breastfeeding. Effect on ability to drive and operate machinery Droxinat affects the ability to drive vehicles and operate machinery. No studies have been conducted on the effect on the ability to drive vehicles and operate machinery. Droxinat is characterized by a side effect such as drowsiness. Therefore, patients should not drive vehicles or operate machinery if they are under the influence of the preparation. Drug interactions Enhances the action of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa). Reduces the toxic effects of ethyl alcohol. Storage conditions and shelf life Store at a temperature not exceeding 25ºC, in the original packaging. Keep out of reach of children. Shelf life: 3 years. Dispensing conditions from pharmacy Pharmaceutical product group III, available without a prescription. Packaging Solution for injection 50 mg/ml in colorless glass ampoules of 2 ml with a break ring. Packed in 10 ampoules (2 x 5 ampoules) of 2 ml solution for injection, with instructions. Manufacturer: Rompharm İlaç San. ve Tic. Ltd. Şti., Turkey.